US generic approvals for Acrux and Cipla

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

US generic approvals for Acrux and Cipla

Generics/News | Posted 16/07/2021 0 Post your comment

In late June 2021, Australian pharmaceutical company Acrux received United State Food and Drug Administration (FDA) approval to market its generic version of Vallant’s Jubila (efinaconazole). In addition, Indian generics maker Cipla received final FDA approval for a generic version of Sunovion Pharmaceuticals Inc’s Brovana, an arformoterol tartrate inhalation solution.

Acrux generic approval
Efinaconazole is a topical solution used to treat toenail fungus.

Acrux sought to release their generic product prior to the Jubila’s patent expirations in the US and filed an abbreviated new drug application for the product in 2018. As part of the settlement and following the US approval, the company is now negotiating with a commercial licensee to commercialize the product in the US.

Cipla generic approval
Arformoterol is a long-acting beta-2 adrenergic agonist (beta-2 agonist). The Brorvana originator is indicated for the long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Cipla’s arformoterol tartrate inhalation solution will be available as 15 mcg/2 mL doses and is now available in the US. The new product hopes to tap into the Brovana market which achieved US sales of approximately US$438 million for the 12-month period ending April 2021, according to IQVIA (IMS Health) data.

New partnerships for Cipla and Samsung Bioepis

FDA approves Glenmark and Cipla generics

LATIN AMERICAN FORUM The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View this week’s headline article: La MHRA del Reino Unido actualiza su directriz para conceder licencia de biosimilares Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Vea el artículo principal de esta semana: La MHRA del Reino Unido actualiza su directriz para conceder licencia de biosimilares Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.